House Passes FDA User Fee Bill; Conference Committee Works to Meet July 4 Goal
The U.S. House of Representatives on Wednesday passed legislation to reauthorize for five years U.S. Food and Drug Administration’s (FDA) authority to assess user fees on prescription drugs and medical devices. Without congressional action, this authority expires September 30. The bill (H.R. 5651) contains provisions aimed at mitigating current and preventing future prescription drug shortages. HANYS supports these provisions as a step toward ameliorating the drug shortage crisis.
The U.S. Senate passed a similar bill (S.3187) before the Memorial Day recess.
HANYS urged all members of the New York State Congressional Delegation to support these bills and is grateful for their continued strong bipartisan support in both chambers.
The bills will move to a conference committee where conferees will work to iron out differences between the two versions. House and Senate leaders have said they would like to have the final bill to President Obama for his signature by July 4. Contact: Chelsi Stevens